Just a friendly reminder amongst all the noise - t
Post# of 148190
Forecast what you think the eventual annual revenue for this drug can be once the first approval is achieved (because that's when the floodgates open to valuation here given the other indications), add the typical pharma multiple to it, factor in shares outstanding, and you have quite a handsome reward, especially from these levels, if your timeframe & diamond hands allow for it.